News

The co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in Study 301, aPhase 3 trial of IV bapineuzumab in patients with

The facility enlargements and resulting jobs increase will generate an estimated $21 million per year in additional payroll and other benefits to local economies, according to the company.

NBTXR3, a nanoparticle formulation of hafnium oxide crystals, is designed for the local treatment of tumors. Under the agreement, Nanobiotix will receive an upfront payment of $1m and

All products will contain ProBiora3, the Company’s patented proprietary blend of three probiotics purposely designed for oral health. Oragenics president and CEO John Bonfiglio said the agreement reinforces

The launch of the Montelukast Sodium Tablets indicated for treating symptoms of asthma and allergic rhinitis follows the expiration of the last patent that provides Merck US market

The company expects to transfer research functions at Urogenix to Astellas’ Tsukuba Research Center in Japan. The closure of the North Carolina-based urology research facility, which at present

The patients in the SWOG S1106 mantle cell lymphoma trial will undergo testing for MRD during treatment and for up to three years of clinical follow up using

PhRMA and AG are analyzing the costs associated with the post-approval trials, identifying cost drivers and variations. The research will leverage negotiated clinical costs from Medidata Grants Manager

As part of the agreement, Chiesi will distribute the product in Europe, Turkey and former CIS countries including promoting the drug, identifying patients and handling reimbursements. Kamada will